Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Cardiogen Dosing Protocol: 20 mg Vial — Cardiac Bioregulator Guide

Cardiogen (Ala-Glu-Asp-Pro tetrapeptide) Russian heart bioregulator dosing guide — cardiac cytoprotection, cardiomyocyte gene expression normalization, and anti-aging cardiac support.

Go to peptide profileCalculate your dose

Quickstart highlights

Cardiogen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator developed by V.K.

  • Concentration: 2 mg/mL (20 mg vial + 10 mL bacteriostatic water, in 2.5 mL portions).
  • At 2 mg/mL: 200 µg = 10 units once daily for 10 consecutive days.
  • One 20 mg vial provides 100 doses at 200 µg — 10 complete 10-day courses.
  • Khavinson bioregulator research: organ-specific peptide accumulation normalizes gene expression in aging tissue.
  • Inject in the evening; 2–3 courses per year is standard Russian anti-aging clinic protocol.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-2 (10-day course)20010Once daily (evening)200 µg — 10 units; standard 10-day intensive course; one 20 mg vial provides 100 doses
Maintenance (ongoing)20010Every other day200 µg EOD — long-term cardiac maintenance; 20 mg vial covers ~200 days EOD

Reconstitution steps

  1. Draw 10 mL bacteriostatic water in four 2.5 mL draws; inject slowly down the vial wall.
  2. Swirl gently until dissolved; do not shake.
  3. Final concentration: 2 mg/mL. At 2 mg/mL: 200 µg = 10 units on a U-100 syringe.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days. Reconstitute in 2.5 mL portions for efficient use within the window.

Supplies needed

10_day-week plan

  • 1 vial
  • 10 syringes
  • 2 mL bac water
  • 10 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Provide cardiac cytoprotection and cardiomyocyte gene expression normalization through the Cardiogen tetrapeptide bioregulator, using the standard 10-day intensive course protocol 2–3 times annually.

Off-cycle: 4–6 months between 10-day intensive courses; 2–3 courses per year for anti-aging cardiac support.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days. The 20 mg vial at 200 µg/day provides 100 doses — reconstitute in 2.5 mL portions (5 mg = 25 doses per reconstitution) to stay within the 28-day window.

Injection & tracking tips

  • Inject subcutaneously in the evening — cardiac bioregulators are thought to act during the body's repair phase during sleep.
  • The 10-day intensive course at 200 µg/day is the standard Russian clinical protocol for Cardiogen.
  • Cardiogen is sometimes administered orally (sublingual) in Russian Cytomaxes formulation — injectable form provides higher bioavailability.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Monitor cardiac biomarkers (BNP or NT-proBNP, troponin I/T) at baseline and 3 months post-course.
  • Track resting heart rate and heart rate variability (HRV) weekly using wearable device.
  • ECG at baseline and 3 months post-course to assess cardiac electrical stability.
Log your cycle in the calculator →

How this works & references

Cardiogen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator developed by V.K. Khavinson at the St. Petersburg Institute of Bioregulation. Russian bioregulator research documents tissue-specific peptide bioregulators that accumulate in their target organ and normalize gene expression in aging or diseased cells. Cardiogen is specifically designed for cardiac tissue, where it stimulates cardiomyocyte repair, reduces reactive oxygen species in cardiac mitochondria, and normalizes cardiomyocyte contractile protein gene expression. Khavinson et al. have published multiple Russian-language studies demonstrating improved cardiac function metrics in heart failure and aging patients during 10-day Cardiogen courses.

Sources

  • Source: Khavinson VK et al. — Short peptide bioregulators: organ-specific effects. Ann N Y Acad Sci. 2010;1207:66-75

Frequently asked questions

What does Cardiogen actually do for the heart?
Based on Russian bioregulator research, Cardiogen accumulates in cardiac tissue after injection or oral administration, where it acts as a gene expression modulator — normalizing the transcription of contractile proteins (myosin heavy chain, troponin T), antioxidant enzymes, and mitochondrial biogenesis genes that become dysregulated with aging and ischemic stress. Effects are described as cytoprotective and regenerative rather than acute pharmacological.
Is there Western peer-reviewed evidence for Cardiogen?
Most published evidence is in Russian-language journals. Western peer-reviewed data on Cardiogen specifically is minimal. The broader evidence base for Khavinson short peptide bioregulators is accessible through Khavinson's English publications in Annals of NYAS and Biogerontology, which document general mechanisms of bioregulator peptides including organ-specific accumulation and gene expression normalization.
Can Cardiogen be used after a heart attack?
Russian bioregulator clinical applications include post-myocardial infarction cardioprotection as part of integrative cardiac rehabilitation. As with all experimental compounds, this should be done only under cardiologist supervision and is not a replacement for standard post-MI pharmacotherapy (aspirin, beta-blockers, statins, ACE inhibitors/ARBs).
Is Cardiogen the same as Epithalon but for the heart?
Epithalon (AEDG) targets the pineal gland and has systemic anti-aging effects including telomerase activation. Cardiogen (AEDP) is organ-specific to cardiac tissue. Both are short tetrapeptide bioregulators from Khavinson's research group, but with different amino acid sequences and target tissues. They can be combined for comprehensive anti-aging support.
What is the injectable dose compared to the oral Cytomaxes tablets?
The Russian oral Cytomaxes (sublingual tablet) Cardiogen formulation uses 200 µg per tablet, same dose as injection. Sublingual absorption bypasses first-pass hepatic metabolism but provides lower and more variable systemic bioavailability than SC injection. Injectable Cardiogen is preferred for medical protocols requiring reliable systemic exposure.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →